Current issues and controversies in the classification of pediatric hepatocellular tumors

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 780-784

  López Terrada, Dolores ^a   Zimmermann, Arthur ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biology; Hepatoblastoma; Pathology; Prognosis

Indexed keywords

CANCER CLASSIFICATION; CANCER PROGNOSIS; CONSENSUS; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; MITOSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHABDOID TUMOR; UNDIFFERENTIATED CARCINOMA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; FEMALE; GENES, NEOPLASM; HEPATOBLASTOMA; HUMANS; INFANT; INFANT, NEWBORN; LIVER NEOPLASMS; MALE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84866168977     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24214     Document Type: Review

References (50)

1. Darbari A, Sabin KM, Shapiro CN, et al. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003; 38: 560-566.
2. Finegold MJ. Hepatic tumors in childhood. In: Russo P, Ruchelli E, Piccoli DA, editors. Pathology of pediatric gastrointestinal and liver disease. New York: Springer Verlag; 2004.
3. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol 1983; 14: 512-537.
4. Stocker JT. Hepatic tumors in children. Philadelphia: Lippincott, Williams and Wilkins; 2001. 259-281; viii-ix p.
5. Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 1989; 64: 1082-1095.
6. Haas JE, Feusner JH, Finegold MJ. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer 2001; 92: 3130-3134.
7. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000; 18: 2665-2675.
8. Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer 1967; 20: 396-422.
9. Kasai M, Watanabe I. Histologic classification of liver-cell carcinoma in infancy and childhood and its clinical evaluation. A study of 70 cases collected in Japan. Cancer 1970; 25: 551-563.
10. von Schweinitz D, Hecker H, Harms D, et al. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma-A report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 1995; 30: 845-852.
11. Malogolowkin MH, Katzenstein HM, Krailo M, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology. Pediatr Blood Cancer 2011; 29: 3301-3306.
12. Zimmermann A. Hepatoblastoma with cholangioblastic features ('cholangioblastic hepatoblastoma') and other liver tumors with bimodal differentiation in young patients. Med Pediatr Oncol 2002; 39: 487-491.
13. Gornicka B, Ziarkiewicz-Wroblewska B, Michalowicz B, et al. Immature hepatic tumor of bimodal differentiation in a young adult patient: A novel lesion expressing beta-catenin and mimicking a distinct phase of hepatogenesis. J Hepatol 2001; 34: 955-961.
14. Gonzalez-Crussi F, Upton MP, Maurer HS. Hepatoblastoma. Attempt at characterization of histologic subtypes. Am J Surg Pathol 1982; 6: 599-612.
15. Zimmermann A. The emerging family of hepatoblastoma tumours: From ontogenesis to oncogenesis. Eur J Cancer 2005; 41: 1503-1514.
16. Conran RM, Hitchcock CL, Waclawiw MA, et al. Hepatoblastoma: The prognostic significance of histologic type. Pediatr Pathol 1992; 12: 167-183.
17. Prokurat A, Kluge P, Kosciesza A, et al. Transitional liver cell tumors (TLCT) in older children and adolescents: A novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol 2002; 39: 510-518.
18. Gonzalez-Crussi F. Undifferentiated small cell ("anaplastic") hepatoblastoma. Pediatr Pathol 1991; 11: 155-161.
19. Stocker JT. Hepatoblastoma. Semin Diagn Pathol 1994; 11: 136-143.
20. De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience. Eur J Cancer 2008; 44: 545-550.
21. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, et al. Small cell undifferentiated variant of hepatoblastoma: Adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009; 52: 328-334.
22. López-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol 2009; 40: 783-794.
23. Joshi VV, Kaur P, Ryan B, et al. Mucoid anaplastic hepatoblastoma. A case report. Cancer 1984; 54: 2035-2039.
24. Zynger DL, Gupta A, Luan C, et al. Expression of glypican 3 in hepatoblastoma: An immunohistochemical study of 65 cases. Hum Pathol 2008; 39: 224-230.
25. Ramsay AD, Bates AW, Williams S, et al. Variable antigen expression in hepatoblastomas. Appl Immunohistochem Mol Morphol 2008; 16: 140-147.
26. Brotto M, Finegold MJ. Distinct patterns of p27/KIP 1 gene expression in hepatoblastoma and prognostic implications with correlation before and after chemotherapy. Hum Pathol 2002; 33: 198-205.
27. Adesina AM, Nguyen Y, Guanaratne P, et al. FOXG1 is overexpressed in hepatoblastoma. Hum Pathol 2007; 38: 400-409.
28. Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: A Pediatric Oncology Group study. J Clin Oncol 1993; 11: 96-99.
29. Feusner JH, Krailo MD, Haas JE, et al. Treatment of pulmonary metastases of initial stage I hepatoblastoma in childhood. Report from the Childrens Cancer Group. Cancer 1993; 71: 859-864.
30. Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 53: 1016-1022.
31. Russo P, Biegel JA. SMARCB1/INI1 alterations and hepatoblastoma: Another extrarenal rhabdoid tumor revealed? Pediatr Blood Cancer 2009; 52: 312-313.
32. Roberts CW, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 2009; 8: 412-416.
33. Judkins AR. Immunohistochemistry of INI1 expression: A new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol 2007; 14: 335-339.
34. Roberts CW, Orkin SH. The SWI/SNF complex-Chromatin and cancer. Nat Rev Cancer 2004; 4: 133-142.
35. Sansam CG, Roberts CW. Epigenetics and cancer: Altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle 2006; 5: 621-624.
36. Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery: Impact of SWI/SNF perturbations in cancer. Cancer Res 2009; 69: 8223-8230.
37. Morozov A, Lee SJ, Zhang ZK, et al. INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors. Clin Cancer Res 2007; 13: 4721-4730.
38. Parada LA, Limon J, Iliszko M, et al. Cytogenetics of hepatoblastoma: Further characterization of 1q rearrangements by fluorescence in situ hybridization: An international collaborative study. Med Pediatr Oncol 2000; 34: 165-170.
39. Tomlinson GE, Douglass EC, Pollock BH, et al. Cytogenetic evaluation of a large series of hepatoblastomas: Numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer 2005; 44: 177-184.
40. Jeng YM, Wu MZ, Mao TL, et al. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000; 152: 45-51.
41. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21: 4863-4871.
42. Eichenmuller M, Gruner I, Hagl B, et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009; 49: 482-490.
43. Von Schweinitz D, Fuchs J, Gluer S, et al. The occurrence of liver growth factor in hepatoblastoma. Eur J Pediatr Surg 1998; 8: 133-136.
44. Hartmann W, Kuchler J, Koch A, et al. Activation of phosphatidylinositol-3′-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 2009; 15: 4538-4545.
45. Honda S, Arai Y, Haruta M, et al. Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. Br J Cancer 2008; 99: 1891-1899.
46. Yamada S, Ohira M, Horie H, et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: Identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004; 23: 5901-5911.
47. Cairo S, Armengol C, De Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14: 471-484.
48. Adesina AM, López-Terrada D, Wong KK, et al. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 2009; 40: 843-853.
49. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006; 44: 1012-1024.
50. Cairo S, Wang Y, de Reynies A, et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci USA 2010; 107: 20471-20476.